MasriAhmadMD Profile Banner
Ahmad Masri Profile
Ahmad Masri

@MasriAhmadMD

Followers
9K
Following
33K
Media
5K
Statuses
24K

@OHSUCardio | #HCM #Amyloid #Fabry #LVH #DCM #Cardiomyopathies #Cardiogenetics #Echofirst #WhyCMR #CVNuc #RCTs | Views are mine & not medical advice

Portland, OR
Joined April 2014
Don't wanna be here? Send us removal request.
@MasriAhmadMD
Ahmad Masri
17 hours
Great work here by @SrihariNaiduMD and all authors. Lots of work went into putting this together. Take a look when you have a chance .#CardioTwitter.
@SrihariNaiduMD
Srihari S. Naidu, MD
19 hours
1/2: Coming out Oct 2! . The 3rd Ed of Hypertrophic Cardiomyopathy w/ expanded content, board style Q&A & .4 section editors: . @MasriAhmadMD @tikuowens @MartinMaronMD @mmartinezheart . Amazon Link: or buy from @springerpub for 20% discount (next post)
Tweet media one
1
3
28
@MasriAhmadMD
Ahmad Masri
17 hours
RT @SrihariNaiduMD: 1/2: Coming out Oct 2! . The 3rd Ed of Hypertrophic Cardiomyopathy w/ expanded content, board style Q&A & .4 section….
0
14
0
@MasriAhmadMD
Ahmad Masri
1 day
RT @BrettSperryMD: Case report of HMDP washout at 3hrs in cardiac amyloidosis. Key points:.1. 99mTc has more stable tagging to HMDP than P….
0
10
0
@MasriAhmadMD
Ahmad Masri
3 days
RT @drbennisahmed: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of….
0
3
0
@MasriAhmadMD
Ahmad Masri
3 days
RT @drbennisahmed: Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Cha….
0
13
0
@MasriAhmadMD
Ahmad Masri
8 days
RT @EACVIPresident: 💓 Ready to boost your #HCM expertise?. Join the #EACVI Hypertrophic Cardiomyopathy Imaging Masterclass.📅 2–3 Oct 2025 |….
0
16
0
@MasriAhmadMD
Ahmad Masri
12 days
MAGNITUDE phase III trial: Nex-Z vs placebo in ATTR-CM, will increase sample size to 1200 patients. #CardioTwitter
Tweet media one
2
5
21
@MasriAhmadMD
Ahmad Masri
14 days
RT @drbennisahmed: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy:….
0
5
0
@MasriAhmadMD
Ahmad Masri
14 days
What happens when you go after a founder variant such as LMNA . #cardiotwitter
Tweet media one
Tweet media two
Tweet media three
0
4
28
@MasriAhmadMD
Ahmad Masri
14 days
RT @drbennisahmed: Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. V….
0
18
0
@MasriAhmadMD
Ahmad Masri
19 days
RT @hcmsociety: Don't miss out on a full day of learning. ❤️ Five sessions .❤️Two satellites.❤️Panel discussions.❤️The inaugural Eugene B….
0
6
0
@MasriAhmadMD
Ahmad Masri
19 days
RT @drbennisahmed: Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy. Over a 3‐y….
0
1
0
@MasriAhmadMD
Ahmad Masri
23 days
Chatgpt is very useful but also really good at making stuff up. #cardiotwitter
Tweet media one
3
0
7
@MasriAhmadMD
Ahmad Masri
27 days
RT @drbennisahmed: Diagnostic yield in families to sudden cardiac death victims: a 10-year follow-up study. Long-term follow-up identified….
0
5
0
@MasriAhmadMD
Ahmad Masri
27 days
RT @drbennisahmed: Seek and you shall find: red flags in hypertrophic phenotypes. Clinical red flags in patients presenting with HCM are ef….
0
4
0
@MasriAhmadMD
Ahmad Masri
30 days
RT @Amyloidosis_ARC: 🎉 Congrats to the first ARC #ClinicalFellowship awardees! Thank you for helping shape the next generation of #amyloido….
0
4
0
@MasriAhmadMD
Ahmad Masri
1 month
RT @captainchloride: If you're applying for Nephrology fellowship let @DGlaucomflecken tell you why you need to apply to @OHSUNephrology. T….
0
22
0
@MasriAhmadMD
Ahmad Masri
1 month
RT @Teebi_MD: 🧵Check out our work @JAHA_AHA on 3-year outcomes following septal myectomy in 5,300 obstructive HCM patients. High overall b….
0
10
0
@MasriAhmadMD
Ahmad Masri
1 month
RT @JACCJournals: In this #JACCBTS article, authors demonstrate that repetitive pressure overload in swine develops interstitial fibrosis a….
0
6
0
@MasriAhmadMD
Ahmad Masri
1 month
Targeting the underlying precursor protein is simpler than removing amyloid. Pathophysiology of AL is complex, and having different involved light chains as well makes it harder to develop a singular therapy. I am encouraged by the mention of a specific group that derived.
0
1
7